MediWound Q2 Revenue Falls 46% to $3.1M, Reaffirms $24–26M Full-Year Guidance
MDWD is trading near its 52-week low of $13.54 (2.7% above the low).
Summary
MediWound reported Q2 2026 revenue of $3.1 million, down 46% from $5.7 million a year ago, driven by timing of BARDA-funded development revenue, but beat revenue estimates. Net loss narrowed to $7.4 million ($0.57/share) from $13.3 million ($1.23/share) due to non-cash financial income. The company reaffirmed full-year 2026 revenue guidance of $24–26 million, expecting second-half contributions from the new Master Services Agreement with Vericel under its BARDA contract. EscharEx Phase III VALUE trial enrollment completion and interim assessment are now expected by end of Q1 2027, a slight delay from prior expectations. The stock trades near its 52-week low, reflecting ongoing cash burn and revenue decline. Key watch items: EscharEx interim data and NexoBrid revenue ramp in H2 2026.
At the time of this announcement, MDWD was trading at $13.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.7M. The 52-week trading range was $13.54 to $20.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.